Global Point of Care
Chronic kidney disease (CKD) affects approximately 850 million people worldwide. It is the ninth leading cause of death worldwide, and the third fastest-growing cause of death globally, with rising mortality rates. By 2040, CKD is expected to become the fifth leading cause of years of life lost.1,2,3
If left undetected and untreated, CKD can progress to kidney failure, leading to severe complications and premature mortality. CKD is also a critical component of cardiorenal metabolic diseases, including cardiovascular disease and metabolic disorders.3
Patients with diabetes, hypertension, or cardiovascular risk factors should be assessed at least annually.4
Kidney disease can be prevented, and progression to end-stage kidney disease can be delayed with appropriate access to basic diagnostics and early treatment. With point-of-care testing, primary healthcare providers can do just that – in minutes.
Watch this video to learn why early detection and testing are critical to managing chronic kidney disease and preventing complications.
Recent therapeutic breakthroughs offer new opportunities to prevent or delay kidney disease and mitigate complications such as cardiovascular disease and kidney failure.1 But you can only treat what you know about. Early detection is key.
KDIGO and the International Society of Nephrology (ISN) call for screening of patients with kidney disease risk factors like high blood pressure, diabetes, cardiovascular disease, and a family history of kidney disease, as early treatment can reduce morbidity and mortality rates.5 The American Diabetes Association (ADA) recommends annual screening of people with diabetes for kidney disease.6
Kidney disease screening and risk stratification should consist of a dual assessment of estimated glomerular filtration rate (eGFR) and albuminuria (uACR).5 Identifying renal disease early and monitoring it consistently can make all the difference.
CKM refers to Cardiovascular-Kidney-Metabolic syndrome, a condition characterized by interconnected issues like heart disease, kidney disease, type 2 diabetes, and obesity, which the American Heart Association (AHA) has identified as a specific health condition.9
“1 in 3 US adults have risk factors that contribute to Cardiovascular-Kidney-Metabolic (CKM) Syndrome”10
This definition helps identify individuals at high risk for CKM syndrome-related morbidity and mortality, enabling the initiation of preventive strategies before end-organ damage occurs. It also lays the groundwork for outlining the stages of CKM syndrome, identifying evidence-based best practices for its clinical management, and developing tools to screen and categorize individuals by risk for adverse outcomes.
The increased likelihood of CKM syndrome and its adverse outcomes is further influenced by unfavorable conditions for lifestyle and self-care resulting from policies, economics, and the environment. This comprehensive approach enables the timely initiation of preventive and treatment strategies.
CKM refers to Cardiovascular-Kidney-Metabolic syndrome, a condition characterized by interconnected issues like heart disease, kidney disease, type 2 diabetes, and obesity, which the American Heart Association (AHA) has identified as a specific health condition.9
“1 in 3 US adults have risk factors that contribute to Cardiovascular-Kidney-Metabolic (CKM) Syndrome”10
This definition helps identify individuals at high risk for CKM syndrome-related morbidity and mortality, enabling the initiation of preventive strategies before end-organ damage occurs. It also lays the groundwork for outlining the stages of CKM syndrome, identifying evidence-based best practices for its clinical management, and developing tools to screen and categorize individuals by risk for adverse outcomes.
The increased likelihood of CKM syndrome and its adverse outcomes is further influenced by unfavorable conditions for lifestyle and self-care resulting from policies, economics, and the environment. This comprehensive approach enables the timely initiation of preventive and treatment strategies.
Rapid point-of-care testing such as Afinion™ ACR assay enable healthcare providers to detect and manage the onset of kidney conditions. The earliest sign of kidney disease is increased excretion of albumin in urine (albuminuria). ACR is the recommended method by KDIGO, ISN and ADA to determine albuminuria. The KDIGO CKD guidelines3 highlight the advantages of using point-of-care testing for creatinine and urine albumin measurement (Recommendation 1.4.1).5-8
By combining immediate treatment with the necessary lifestyle changes - such as maintaining blood glucose, blood pressure and cholesterol levels - many people with diabetes are able to delay the onset of kidney disease complications – or prevent them altogether.11
Immediate results mean immediate advice.
People with diabetes and hypertension are at a significantly higher risk of developing kidney damage.11 Identifying and monitoring renal disease in patients with diabetes and hypertension can make all the difference — and Abbott makes it fast and easy with a compact rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care.
Accurate results in approximately 5 minutes.
Part of a multi-assay system, Afinion™ ACR is an in vitro diagnostic test for the quantitative determination of albumin, creatinine and albumin-creatinine ratio in human urine. Measuring ACR is crucial in patients who have chronic conditions, such as diabetes and hypertension, as it serves as a predictive marker for early detection kidney disease.12, 13
Short assay time in approximately 3 minutes.
Afinion™ HbA1c gives you reliable high-quality results conveniently available when and where you need them. This test is used for quantitative determination of glycated hemoglobin (HbA1c) in human whole blood. It also provides the immediate test results you need for improved diabetic control, better patient outcomes, and enhanced clinic efficiencies.
The International Diabetes Federation projects a global diabetes incidence of ~643 million by 2030. Diabetic kidney disease (DKD) occurs in up to 40% of patients with diabetes.
Chronic Kidney Disease (CKD) affects 1 in 3 Americans, and only 10% of individuals with CKD know they have the disease.1
A Leader In Rapid Point-of-care Diagnostics.
©2025 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.
